StockData
GT Biopharma, Inc. logo

GT Biopharma, Inc. (GTBP) stock

GTBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 5/30
$3.18−0.25 (-7.29%)

Close on Nov 19, 2026Market cap $143.45MP/E –Yield –

GT Biopharma operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

GT Biopharma's operating income for the twelve months ending Jun 30, 2026 was -$16.34M. For fiscal 2025 it was -$12.42M. The highest annual figure on record is $16.06M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$12.42M–
FY2024Dec 31, 2024-$14.36M–
FY2023Dec 31, 2023-$13.58M–
FY2022Dec 31, 2022-$21.26M–
FY2021Dec 31, 2021-$57.52M–
FY2020Dec 31, 2020-$6.76M-142.1%
FY2019Dec 31, 2019$16.06M–
FY2018Dec 31, 2018-$250.07M–
FY2017Dec 31, 2017-$135.57M–
FY2016Dec 31, 2016-$9.37M–
FY2015Dec 31, 2015-$8.93M–
FY2014Dec 31, 2014-$2.40M–
FY2013Dec 31, 2013-$793.00K–
FY2012Dec 31, 2012-$3.51M–
FY2011Dec 31, 2011-$3.93M–
FY2010Dec 31, 2010-$2.50M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$4.51M–
Q1 FY2026Mar 31, 2026-$2.85M–
Q4 FY2025Dec 31, 2025-$5.60M–
Q3 FY2025Sep 30, 2025-$3.38M–
Q2 FY2025Jun 30, 2025-$1.51M–
Q1 FY2025Mar 31, 2025-$1.93M–
Q4 FY2024Dec 31, 2024-$3.76M–
Q3 FY2024Sep 30, 2024-$3.60M–
Q2 FY2024Jun 30, 2024-$3.91M–
Q1 FY2024Mar 31, 2024-$3.09M–
Q4 FY2023Dec 31, 2023-$3.17M–
Q3 FY2023Sep 30, 2023-$3.12M–
Q2 FY2023Jun 30, 2023-$3.62M–
Q1 FY2023Mar 31, 2023-$3.67M–
Q4 FY2022Dec 31, 2022-$5.78M–
Q3 FY2022Sep 30, 2022-$7.02M–
Q2 FY2022Jun 30, 2022-$3.01M–
Q1 FY2022Mar 31, 2022-$5.44M–
Q4 FY2021Dec 31, 2021-$18.18M–
Q3 FY2021Sep 30, 2021-$5.95M–
Q2 FY2021Jun 30, 2021-$4.38M–
Q1 FY2021Mar 31, 2021-$29.00M-2810.5%
Q4 FY2020Dec 31, 2020-$2.19M-107.0%
Q3 FY2020Sep 30, 2020-$1.95M–
Q2 FY2020Jun 30, 2020-$1.56M–
Q1 FY2020Mar 31, 2020$1.07M–
Q4 FY2019Dec 31, 2019$31.25M–
Q3 FY2019Sep 30, 2019-$8.86M–
Q2 FY2019Jun 30, 2019-$2.28M–
Q1 FY2019Mar 31, 2019-$4.06M–
Q4 FY2018Dec 31, 2018-$3.09M–
Q3 FY2018Sep 30, 2018-$234.66M–
Q2 FY2018Jun 30, 2018-$5.16M–
Q1 FY2018Mar 31, 2018-$7.16M–
Q4 FY2017Dec 31, 2017-$5.89M–
Q3 FY2017Sep 30, 2017-$126.86M–
Q2 FY2017Jun 30, 2017-$1.29M–
Q1 FY2017Mar 31, 2017-$1.54M–
Q4 FY2016Dec 31, 2016-$822.00K–
Q3 FY2016Sep 30, 2016-$2.53M–

More GT Biopharma figures

See a number that looks wrong?